[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,50,84,115,142,182,202,229,257,287,311,334,364,389,411,433,456,482,512,565,594,617,643,680,700],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100546822","baker-gordon-syndrome-natural-history-study-100546822",false,"NCT06399952","Baker Gordon Syndrome Natural History Study","A Prospective, Longitudinal and Observational Natural History Study for Children and Adults With Baker Gordon Syndrome - Genetic Autism Alliance","BAGOS","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of Baker Gordon syndrome.\n* 0-99 years\n* Ability to send medical records and diagnostic test results.\n* Ability to complete tests and questionnaires.\n\nExclusion Criteria:\n\n• The presence of another condition or co-morbidity unrelated to Baker Gordon syndrome, that affects neurodevelopment.\n\nIn this study, the primary caregivers\u002FLAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.\n\nCaregivers\u002FLAR will have to meet the following inclusion criteria:\n\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a Baker Gordon Syndrome.\n* Willingness to follow study procedures, as assessed by the research team.\n* Willingness to sign the consent form.\n* Ability to understand all the information regarding the study, as assessed by the research team.\n\nCaregivers\u002FLAR Exclusion Criteria:\n\n• Less than 18 years old.","ALL","0 Years","99 Years",{"count":22,"type":23},50,"ESTIMATED","OBSERVATIONAL","The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.",[27,28,29,30,31,32,33],"Rare Diseases","Autism or Autistic Traits","Development Delay","SYT-SSX Fusion Protein Expression","Sleep Disorder","Epilepsy, Generalized","Motor Delay",[35,16,36],"Baker Gordon Syndrome","Synaptotagmin 1-Associated Neurodevelopmental Disorder","RECRUITING","2026-06-01",{"date":40,"type":41},"2026-06-03","ACTUAL",{"date":43,"type":41},"2024-04-30",{"date":45,"type":23},"2027-05-05",{"name":47,"class":48},"University of Missouri-Columbia","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":49},"100305377","phase-1-cerebral-blood-flow-and-ventilatory-responses-during-sleep-in-normoxia-and-intermittent-hypoxia-100305377","NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking",true,"18 Years","45 Years",{"count":61,"type":23},12,"INTERVENTIONAL",[64,65],"PHASE1","PHASE2","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[68,69,70,31,71,72,73,74],"Obstructive Sleep Apnea of Adult","Hypoxia, Brain","Sleep Apnea","Stroke","Blood Pressure","Endothelial Dysfunction","Oxidative Stress","2026-04-27",{"date":77,"type":41},"2026-05-01",{"date":79,"type":41},"2023-01-01",{"date":81,"type":23},"2027-12-30",{"name":83,"class":48},"University of Calgary",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":62,"phases":96,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":49},"100468666","home-apnea-testing-in-children-trial-100468666","NCT05382754","Home Apnea Testing in CHildren Trial","Home Sleep Apnea Testing Compared to In-lab Polysomnography for the Evaluation of Obstructive Sleep Apnea in Children","HATCH","Inclusion Criteria:\n\n* Male and female children age 5-12 years old inclusive\n* Referred for diagnostic PSG at the Children's Hospital of Philadelphia (CHOP) Sleep Laboratory for evaluation of OSA as part of clinical care\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria:\n\n* Children without Down syndrome who have had a PSG within 3 years of enrollment\n* Children with Down syndrome who have had a PSG within 1 year of enrollment.\n* Children with a history of hypoventilation or hypoxemia or who require supplemental oxygen or positive airway pressure during sleep\n* Children with a tracheostomy or tracheocutaneous fistula\n* Children who live in a facility without their parent","5 Years","12 Years",{"count":95,"type":23},317,[97],"NA","This clinical trial will compare home sleep apnea testing with the gold standard in-lab polysomnography in terms of 1) accuracy, 2) therapeutic decision-making, and 3) parent\u002Fchild acceptability in children referred for evaluation of obstructive sleep apnea.",[100,31,101,102],"Sleep Apnea, Obstructive","Sleep Apnea Syndromes","Sleep Disturbance",[104,105],"obstructive sleep apnea","home sleep apnea testing","2026-04-16",{"date":108,"type":41},"2026-04-21",{"date":110,"type":41},"2023-03-29",{"date":112,"type":23},"2027-07",{"name":114,"class":48},"Children's Hospital of Philadelphia",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":57,"sex":122,"minAge":58,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":62,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":49},"100630293","the-effects-of-yoga-on-pregnant-women-100630293","NCT07485790","The Effects of Yoga on Pregnant Women","The Effects of Yoga on Stress, Sexual Life Quality, and Sleep Habits in Pregnant Women: A Randomized Controlled Study","Inclusion Criteria:\n\n* In their third trimester,\n* Able to read and write in Turkish,\n* Use a smartphone and have internet access,\n* Have no communication barriers,\n* Voluntarily agree to participate in the research.\n\nExclusion Criteria:\n\n* Pregnant women with any risk factors during pregnancy,\n* Pregnant women with any chronic illness,\n* Pregnant women with a diagnosed psychological problem,\n* Pregnant women with any exercise restrictions imposed by a physician,\n* Pregnant women participating in a different training program (meditation, relaxation, etc.)","FEMALE",{"count":124,"type":23},70,[97],"It is thought that a yoga intervention administered to pregnant women will reduce stress levels, enhance sexual quality of life, and positively affect sleep habits. According to the power analysis results, the study must include at least 70 pregnant women (35 in the experimental group and 35 in the control group). Data will be collected through a Personal Information Form, the Perceived Stress Scale (PSS), the Sexual Quality of Life Questionnaire-Female (SQLQ-F), and a Sleep Habits Form. In this study, the yoga practice will be administered to the pregnant women in the experimental group by the researcher.",[31,128],"Stress",[130,131,132],"sexual quality of life","pregnant women","yoga","2026-03-17",{"date":135,"type":41},"2026-03-20",{"date":137,"type":41},"2026-03-15",{"date":139,"type":23},"2026-09-01",{"name":141,"class":48},"Amasya University",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":57,"sex":18,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":62,"phases":153,"briefSummary":154,"conditions":155,"keywords":165,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":49},"100617156","impact-of-lifestyle-on-health-maintenance-a-randomized-controlled-trial-100617156","NCT07314957","Impact of Lifestyle on Health Maintenance: A Randomized Controlled Trial","The Role of Lifestyle in Maintaining Health: Biological, Psychological and Social Responses of the Organism to Lifestyle","LifeHealth-RCT","Inclusion Criteria:\n\n* adults aged 20 years and older\n* overweight or obesity (BMI ≥25 kg\u002Fm²),\n* stable body weight over the past 6 months\n* physically inactive.\n\nExclusion Criteria:\n\n* HbA1c \\>12%\n* insulin therapy\n* severe psychiatry and severe chronic illnesses of parents\n* diseases of the hypothalamus and pituitary and adrenal gland\n* mobility restriction\n* tetraplegia\n* use of obesity pharmacotherapy\n* malignant disease and chemotherapy\n* pregnancy","20 Years",{"count":152,"type":23},120,[97],"This study aims to evaluate the impact of public health interventions on changes in healthy lifestyle habits over time and their subsequent effects on health outcomes. The investigators hypothesize that exposing at-risk populations to structured physical activity programs, education on healthy nutrition, promotion of the Mediterranean diet, and workshops focused on strengthening psychological resilience will lead to improvements in anthropometric, oxidative, metabolic, and psychological parameters. Anthropometric and laboratory measures will be collected at multiple time points throughout the study. The longitudinal follow-up will span 12 months. It is anticipated that sustained adherence to healthy lifestyle behaviors will result in positive lifestyle changes and enhanced health-related quality of life.",[156,157,158,159,160,128,31,161,162,163,164],"Metabolic Syndrome","Inactivity\u002FLow Levels of Exercise","Unhealthy Diet","Unhealthy Alcohol Use","Smoking Behaviors","Obesity & Overweight","Anxiety","Depressed Mood","Emotional Eating Behaviour",[166,167,168,169,128,170,171,172],"Habits","Lifestlye","Nutrition","Phisical activity","Metabolic syndrome","Mental health","Sleep","NOT_YET_RECRUITING","2026-02-09",{"date":176,"type":41},"2026-02-12",{"date":139,"type":23},{"date":179,"type":23},"2027-12-31",{"name":181,"class":48},"University of Zadar",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":62,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100623337","impact-of-relaxation-sessions-using-a-virtual-reality-application-on-the-sleep-quality-of-caregivers-working-night-shifts-100623337","NCT07395323","Impact of Relaxation Sessions Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shifts","Impact of Using a Virtual Reality Application on the Sleep Quality of Caregivers Working Night Shifts","Luciole","Inclusion Criteria:\n\n* State-certified nurse or nursing assistant (GHU, GHPG staff)\n* Regularly working night shifts and on duty in the units\n* Age 18 years and over\n* Informed individuals who have signed written consent\n* Individuals affiliated with a social security scheme and must be able to understand and read French.\n\nExclusion Criteria:\n\n* No possibility of follow-up (subjects on fixed-term contracts, ongoing transfers, student reinforcements, etc.)\n* Subjects with insufficient command of the French language, preventing them from taking the tests\n* Pregnant or breastfeeding women (disruption of the sleep cycle), or women with young children.\n* Individuals with a pacemaker or any other implanted medical device, unless medically advised otherwise (due to the radio-magnetic waves emitted by the virtual reality headset)\n* Individuals with epilepsy.",{"count":5,"type":23},[97],"This project aims to evaluate the impact of relaxation sessions conducted using a virtual reality device on the sleep quality of night-shift healthcare workers. The intervention specifically targets the immediate post-night-shift period, a critical time for recovery, by offering immersive guided relaxation experiences designed to reduce anxiety and promote both mental and physiological relaxation.",[31],"2026-02-06",{"date":174,"type":41},{"date":197,"type":23},"2026-02-01",{"date":199,"type":23},"2027-05-01",{"name":201,"class":48},"Centre Hospitalier St Anne",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":62,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":49},"100592194","evaluation-of-urolithin-a-and-fisetin-on-improving-sleep-and-aging-biomarkers-100592194","NCT06990256","Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers","Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 30-75 years;\n* Total score \\> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment;\n* Able to use personal mobile devices for WeChat, internet access, and related operations;\n* Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study;\n* Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period;\n\nExclusion Criteria:\n\n* Participation in any clinical trials or dietary\u002Fexercise intervention programs within the past 3 months or concurrently;\n* Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications;\n* Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months;\n* Severe diseases affecting inflammatory levels and\u002For endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction);\n* Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.;\n* Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months;\n* Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.","30 Years","75 Years",{"count":212,"type":23},80,[97],"The goal of this clinical trial is to evaluate the effects of Urolithin A (UA) and Fisetin on improving sleep and aging biomarkers in middle-aged and older adults. The main questions it aims to answer are:\n\nCan UA and Fisetin improve sleep quality in middle-aged and older adults? Do these substances have a positive effect on aging biomarkers, such as inflammation, oxidative stress, and aging-related proteins? Researchers will compare four groups: Placebo group (a look-alike substance that contains no drug), 500 mg UA group, 500 mg Fisetin group and 300 mg UA + 200 mg Fisetin group.\n\nParticipants will:\n\nTake the assigned capsules daily after breakfast for 12 weeks. Attend three clinic visits (baseline \\[Week 0\\], mid-intervention \\[Week 4\\], and post-intervention \\[Week 12\\]) including blood tests, sleep quality assessments (PSQI scale, actigraphy, polysomnography), and analysis of aging biomarkers (DNA methylation, inflammatory cytokines, etc.). Keep a sleep diary, complete a dietary survey, assess mental health, and measure frailty indicators. Provide stool and urine samples at baseline and post-intervention for gut microbiome and metabolite analysis. This trial aims to provide scientific evidence for the development of new nutritional intervention strategies to improve the healthy aging.",[31,216],"Aging",[218,219,31,216],"Urolithin A","Fisetin","2026-01-16",{"date":222,"type":41},"2026-01-21",{"date":224,"type":41},"2025-09-16",{"date":226,"type":23},"2026-12-30",{"name":228,"class":48},"Huazhong University of Science and Technology",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":150,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":62,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":49},"100435373","sleepup-digital-cbti-based-platform-for-insomnia-100435373","NCT04949360","SleepUp Digital CBTi-based Platform for Insomnia","Evaluation of SleepUp Digital CBTi-based Platform in the Treatment of Insomnia","Inclusion Criteria:\n\n* Literate Brazilian portuguese speakers.\n* Insomnia symptoms (as measured by ISI).\n* An Android-based smartphone or tablet with access to the Internet.\n\nExclusion Criteria:\n\n* Previous experience with CBTi.\n* Use of sleeping pills or any other treatment for insomnia for two or more days a week in the last three months.","60 Years",{"count":238,"type":23},280,[97],"Cognitive-Behavioral Therapy for insomnia (CBTi) is a well-established therapeutic intervention for insomnia. SleepUp provides a digital therapeutics platform based on CBTi and additional features. This clinical trial aims at analyzing the efficacy of the CBTi-based platform offered by SleepUp in reducing symptoms of insomnia and will be conducted in 2 phases.\n\nPhase 1\n\nThe sample will be composed of 160 individuals, both males and females, from 20 to 60 years old, with insomnia symptoms considered as at least mild. Those who accept to participate will be randomized and distributed in four groups:\n\n* Standard CBTi (CBTi-S): This treatment consists of an eight-week treatment composed by weekly and structure appointments with board-certified sleep psychologists. The appointments will be made remotely (video calls with psychologists).\n* Minimal intervention - Sleep hygiene (MI-SH): This group will receive an educational program on sleep hygiene through the SleepUp app. Its content covers topics that are also covered in the online CBTi sessions. This procedure is more adequate as a control than the commonly used no treatment or waiting list controls, due to the behavioral\n* Online CBTI (CBTI-O): This group will receive access to an eight-weeks CBTi-based treatment through the SleepUp app. The participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform.\n* Online CBTi + additional features (CBTi-O+): This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.\n\nAll participants in all groups will be assessed periodically throughout the eight weeks of intervention with standard sleep questionnaires and sleep logs. Equivalent intervals will be applied to the MI-SH group.\n\nPhase 2\n\nThis phase will comprise 120 individuals, both males and females, from 20 to 60 years old, with insomnia symptoms considered as at least mild. Those who accept to participate will be randomized and distributed in three groups:\n\n* Minimal intervention - Sleep hygiene (MI-SH): This group will receive an educational program on sleep hygiene through the SleepUp app. Its content covers topics that are also covered in the online CBTi sessions. This procedure is more adequate as a control than the commonly used no treatment or waiting list controls, due to the behavioral\n* Online CBTI (CBTI-O): This group will receive access to an eight-weeks CBTi-based treatment through the SleepUp app. The participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform.\n* Online CBTi + additional features (CBTi-O+): This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.\n\nAll participants in all groups will be assessed periodically throughout the eight weeks of intervention with standard sleep questionnaires and sleep logs. Equivalent intervals will be applied to the MI-SH group.",[242,31,243],"Insomnia","Sleep Hygiene",[242,172,245,246],"Cognitive-behavioral therapy","CBTi","2025-12-20",{"date":249,"type":41},"2025-12-29",{"date":251,"type":41},"2025-05-19",{"date":253,"type":23},"2026-12-01",{"name":255,"class":256},"SleepUp Tecnologia em Saúde Ltda","INDUSTRY",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":62,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100612568","overweight-and-obesity-in-adolescents---sleep-behavioral-intervention-100612568","NCT07255274","Overweight and Obesity in Adolescents - Sleep Behavioral Intervention","Treatment of Overweight and Obesity in Adolescents - Impact of a Sleep Behavioral Intervention - SLEEP-OB","SLEEP-OB","Inclusion Criteria:\n\n1. Informed consent from legal guardians and assent\u002Fconsent from the adolescent;\n2. Age between 13 and 17 years at the time of consent;\n3. Diagnosis of overweight (BMI z-score \\> 1 and ≤ 2) or obesity (BMI z-score \\> 2), according to WHO criteria;\n4. Sleep deprivation or poor sleep quality, based on the initial screening questionnaire.\n\nExclusion Criteria:\n\n1. Secondary obesity (e.g., hypothalamic, genetic, or endocrine causes);\n2. Comorbid psychiatric or neurological disorders (e.g., epilepsy, autism spectrum disorder) that affect sleep;\n3. Current treatment with selective serotonin reuptake inhibitors (SSRIs) or other medications affecting sleep.","13 Years","17 Years",{"count":268,"type":23},126,[97],"Sleep plays a crucial role in energy balance, alongside diet and physical activity. Research has linked poor sleep quality and short sleep duration to obesity and cardiometabolic risk, such as insulin resistance and hypertension. The nature of this association is complex, and several mechanims have been suggested.\n\nScientific evidence suggests that sleep interventions may provide additional benefits in optimizing the effectiveness of overweight\u002Fobesity treatment in pediatric populations. Although some studies have explored this hypothesis, methodological heterogeneity hampers clear interpretation of the results.\n\nThe main goal of this clinical trial is is to evaluate the efficacy of a sleep behavioral intervention, combined with standard obesity treatment, in reducing adiposity (measured by BMI z-score, fat mass percentage, or fat-free mass index) in adolescents with overweight or obesity.\n\nThis randomized controlled trial will compare a control group receiving treatment as usual (or standard obesity treatment) with an intervention group receiving treatment as usual plus a sleep behavioral intervention.\n\nParticipants will be randomized into two groups: intervention and control. Throughout the study period, all medical consultations will include standard interventions focused on nutrition, physical activity\u002Fsedentary behavior, and other lifestyle factors. The sleep-focused intervention will be delivered by psychologists.\n\nParticipants will attend clinic visits every two months during the 6-month intervention period, and every three months during the subsequent 6-month follow-up period.",[272,31],"Obesity and Overweight",[274,172,275,276],"Obesity","Behavioral intervention","Adolescents","2025-11-19",{"date":279,"type":41},"2025-12-01",{"date":281,"type":41},"2025-06-03",{"date":283,"type":23},"2026-12",{"name":285,"class":48},"University of Beira Interior",2,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":57,"sex":18,"minAge":294,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":62,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":49},"100515061","niaimproving-function-and-well-being-by-improving-patient-memory-transdiagnostic-sleep-and-circadian-treatment-100515061","NCT05986604","NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment","NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment","Inclusion criteria:\n\n1. Aged 50 years and older;\n2. English language fluency;\n3. Experiencing a mobility impairment;\n4. Low income;\n5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 \"quite a bit\" or 5 \"very much\" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions.\n6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment.\n7. Able\u002Fwilling to give informed consent.\n\nExclusion criteria:\n\n1. Severe untreated sleep disordered breathing (AHI\\>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale \\>10);\n2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care);\n3. Homelessness;\n4. Night shift work \\>2 nights per week in the past 3 months;\n5. Substance abuse\u002Fdependence only if it makes participation in the study unfeasible;\n6. Suicide risk sufficient to preclude treatment on an outpatient basis.","50 Years",{"count":296,"type":23},178,[97],"Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.",[31,300,301],"Circadian Dysregulation","Memory Impairment","2025-11-18",{"date":304,"type":41},"2025-11-24",{"date":306,"type":41},"2024-01-04",{"date":308,"type":23},"2028-07-28",{"name":310,"class":48},"University of California, Berkeley",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":62,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":49},"100361804","pilot-study-of-bcaa-on-sleep-100361804","NCT03990909","Pilot Study of BCAA on Sleep","A Pilot Study of Dietary Supplementation With Branched Chain Amino Acids on Sleep","Inclusion Criteria:\n\n* Veteran\n* English Speaking\n* Accessible via phone\n* Sleep problems\n\nExclusion Criteria:\n\n* Decisional impairment\n* Nickel allergy\n* Maple syrup urine disease or family history of disease\n* Allergy to sucralose\n* Currently taking BCAAs","89 Years",{"count":320,"type":23},300,[97],"Individuals will be recruited from the VA Portland Health Care System and the community affiliated with Oregon Health \\& Science University. Traumatic brain injury status will be assessed as a contributing factor. Subjects will be randomized to one of 3 groups (BCAA or one of 2 placebo conditions) and instructed to consume study product twice daily for 21 days. Self-report questionnaires, wrist actigraphy, pressure pain testing, and cognitive function will be assessed pre and post the experimental period.",[31,324],"Traumatic Brain Injury","2025-11-12",{"date":327,"type":41},"2025-11-14",{"date":329,"type":41},"2019-03-01",{"date":279,"type":23},{"name":332,"class":333},"Portland VA Medical Center","FED",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":342,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":62,"phases":346,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":49},"100586705","comparative-effectiveness-of-myofacial-release-vs-cupping-therapy-on-quality-of-life-in-restless-leg-syndrome-with-knee-oa-100586705","NCT06918847","Comparative Effectiveness of Myofacial Release vs Cupping Therapy on Quality of Life in Restless Leg Syndrome With Knee O.A.","Comparative Effectiveness of Myofacial Release vs Cupping Therapy on Quality of Life in Restless Leg Syndrome With Knee O.A.A RCT","RCT","Inclusion Criteria:\n\n1. grade 2, 3 and 4 knee OA by the Kellgren Lawrence classification\n2. Bilateral or unilateral both knee OA\n3. Age 40 to 70 years\n4. Patients who were meeting the International Restless Leg Syndrome Study Group (IRLSSG) eligibility criteria\n\nExclusion Criteria:\n\n1. patients with cognitive dysfunction\n2. Rheumatoid arthritis\n3. patients with neurological disorders\n4. Medical conditions covering (cardiovascular disease, neurological disorders, severe psychiatric illness or pregnancy)","40 Years","70 Years",{"count":345,"type":23},54,[97],"The aim of this study is to determine effectiveness of Myofascial Release and Cupping Therapy on Quality of Life in Restless Leg Syndrome with knee Osteoarthritis. Holding this aim, a Randomized control trial will be conducted at physiotherapy out patient department of Dow Institute of Physical Medicine and Rehabilitation.\n\nThe subjects will first be screened by the principal investigator, physiotherapist, using the criteria of International Restless Leg Syndrome Study Group (IRLSSG). Each selected subject will go for random allocation in one of the two treatment groups with different interventions with the help of a computer-generated randomization sheet. The group A will be provided with myofacial release whereas the group B will receive cupping therapy while cryotherapy and passive lower limb stretches (hamstring and calf muscles) will be applied to both the groups as standard treatment. Assessment will be done at baseline and will re-evaluate at the post intervention session through an assessment form. Physical therapist but not the principal investigator will assess who will be unaware to the type of intervention administered.\n\nOutcome measures will be Pittsburgh sleep quality index, Visual Analog Scale for pain assessment, Restless leg syndrome Quality of life questionnaire (RLS-QOL), International Restless leg syndrome Study Group Rating Scale (IRLSSG RS) and passive straight leg raise (PSLR). Total 12 sessions will be given for duration of 4weeks on alternate days.",[349,31],"Restless Leg Syndrome With Knee OA",[351,352,353,354],"Restless leg syndrome","knee OA","cupping therapy","myofacial release","2025-10-02",{"date":357,"type":41},"2025-10-07",{"date":359,"type":41},"2025-05-05",{"date":361,"type":23},"2026-07",{"name":363,"class":48},"Dow University of Health Sciences",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":62,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":49},"100608499","targeted-intervention-on-sleep-disorders-during-tobacco-or-cannabis-cessation-therapy-100608499","NCT07202351","Targeted Intervention on Sleep Disorders During Tobacco or Cannabis Cessation Therapy","Impact of an Intervention Targeting Sleep Disorders During Tobacco or Cannabis Cessation Therapy: a Randomised Pilot Study","ISAC","Inclusion Criteria:\n\n* patients over 18 years old\n* presenting at the participating addiction treatment centres for a smoking or cabannis use cessation therapy\n* who agree to participate to the study\n* affiliated to the French health insurance system\n\nExclusion Criteria:\n\n* Patients hospitalised during the cessation therapy\n* Patients undergoing sleep disorders treatment\n* Patients participating to another study\n* Patients with psychotic disorders (according the DSM-5 classification)\n* Patients who do not want the additionnal intervention and care if randomised in the intervention group",{"count":212,"type":23},[97],"During a cessation therapy for tobacco or cannabis, sleep disorders are one of the main risk factors of relapse, and a symptom of substance withdrawing. In this study, we make the hypothesis that identifying and managing potential sleep disorders during cessation treatment may contribute to maintain tobacco \u002F cannabis abstinence on the long-term. To evaluate the impact of such intervention, we will conduct a randomised pilot study among patients consulting at two addiction prevention and care centres, for smoking or cannabis use cessation treatment. Control group will benefit of usual care (a multidisciplinary care with individual and group therapies); intervention group will benefit in addition of a systematic screening of sleep disorders, and in case of a diagnosed alteration, they will be addressed to the Chronos centre, for specific care to help them manage and reduce the consequences of their sleep disorders. Participants will be followed over a 6-month period, with visits at 1 and 3 months, to monitor smoking or cannabis cessation, and other criteria associated with their substance use or sleep.",[31],[377,378,379,380],"sleep disorder","tobacco","cannabis","addiction","2025-09-23",{"date":383,"type":41},"2025-10-01",{"date":385,"type":41},"2023-06-05",{"date":387,"type":23},"2026-08-31",{"name":201,"class":48},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100606406","halitosis-sleep-and-mental-health-in-bariatric-surgery-candidates-100606406","NCT07175142","Halitosis, Sleep and Mental Health in Bariatric Surgery Candidates","Assessment of Psychological Distress, Sleep Quality, and Halitosis in Patients With Obesity: Protocol for an Observational Study in the Preoperative Period of Bariatric Surgery","Inclusion Criteria:\n\n* Adults ≥18 years with a diagnosis of obesity\n* Referred for psychological care at the \"Rosinha Viegas\" Interprofessional Outpatient Clinic during preoperative preparation for bariatric surgery (Brazilian public health system - SUS)\n\nExclusion Criteria:\n\n* Individuals with cognitive or neurological limitations that impair understanding or participation in the assessment procedures\n\nIndividuals who refuse or withdraw consent","90 Years",{"count":398,"type":23},110,"This study aims to evaluate psychological distress, sleep quality, and halitosis in obese patients during the preoperative period of bariatric surgery. A total of 110 adults will be assessed using validated questionnaires and a portable halitosis detector. The results may contribute to improving strategies for comprehensive care in this population.",[274,401,402,31,403],"Bariatric Surgery Candidate","Halitosis","Stress, Psychological","2025-09-09",{"date":224,"type":41},{"date":383,"type":23},{"date":408,"type":23},"2026-06-30",{"name":410,"class":48},"University of Nove de Julho",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":343,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":49},"100470835","study-of-disrupted-sleep-in-somali-americans-100470835","NCT05411029","Study of Disrupted Sleep in Somali Americans","Disrupted Sleep in Somali Americans - Implications for Hypertension Risk","Inclusion Criteria:\n\n* Subjects diagnosed with no known history of hypertension, diabetes, or sleep disorders.\n* Self-identify as Somali.\n* Adult males and females who are older than 18 years of age.\n\nExclusion Criteria:\n\n* Anyone under 18 years or over 70 years.\n* Positive pregnancy.",{"count":419,"type":23},240,"The aims of this study are to determine the types and severity of previously undiagnosed sleep deficiencies in otherwise healthy Somali Americans, apply a research framework to define psychosocial, behavioral, environmental, and biological mechanisms mediating sleep deficiencies in Somali Americans, and examine the relationship between sleep deficiencies and increased blood pressure in Somali Americans.",[422,31,423],"Hypertension","Healthy","2025-09-04",{"date":426,"type":41},"2025-09-10",{"date":428,"type":41},"2022-11-15",{"date":430,"type":23},"2031-12",{"name":432,"class":48},"Mayo Clinic",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":150,"maxAge":236,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":49},"100540139","multidimensional-evaluation-of-patients-affected-by-obstructive-apnea-syndrome-osas-before-and-after-ventilotherapy-100540139","NCT06312956","Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy","MULTI-OSAS","Inclusion Criteria:\n\n* OSAS diagnosis (AHI \\> 5)\n* handedness: right\n\nExclusion Criteria:\n\n* previous ventilotherapy\n* neurological and\u002For neurodegenerative conditions\n* Personality disorders, autism spectrum disorders, schizophrenia, psychosis\n* sleep disorders comorbidities (eg., narcolepsy)",{"count":441,"type":23},65,"This observational study aims to evaluate multiple dimensions of health in patients with Obstructive Sleep Apnea Syndrome (OSAS), before and after three weeks of ventilotherapy.\n\nSpecifically, the study aims to identify pre- vs post-treatment differences in the following domains:\n\n* cognitive performance\n* blood expression of biomarkers related to neurodegeneration\n* psychosocial wellbeing\n\nThus, patients will complete the following evaluations before (T0) and after (T1) ventilotherapy:\n\n* neuropsychological standard assessment\n* blood sampling\n* psychosocial self-reported questionnaires",[444,31,445,446,447,448],"Obstructive Sleep Apnea","Well-Being, Psychological","Cognitive Impairment","Cognitive Change","Neurologic Signs","2025-09-02",{"date":404,"type":41},{"date":452,"type":41},"2024-02-29",{"date":283,"type":23},{"name":455,"class":48},"Istituto Auxologico Italiano",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":93,"maxAge":20,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":481},"100523281","a-prospective-study-to-evaluate-the-wp-in-comparison-to-psg-in-patients-suspected-of-sleep-disorders-100523281","NCT06093633","A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders","A Prospective Study to Evaluate the WatchPAT in Comparison to Polysomnography (PSG) Gold Standard in Patients Suspected of Sleep Disorders","Inclusion Criteria:\n\n* Age between 12-99\n* Subjects that are able to read understand and sign the informed consent form of the study or by parents of subjects that are less than 18 years of age that are referred to undergo an overnight sleep study in the clinical sleep laboratory\n* Subjects suspected of having sleep disorders or with comorbidities relevant to central sleep apnea.\n\nExclusion Criteria:\n\n* Permanent pacemaker: atrial pacing or VVI without sinus rhythm.\n* Finger deformity that precludes adequate sensor appliance.",{"count":464,"type":23},600,"The current study is a prospective blinded study to collect data regarding the performance of the WP device in detecting sleep disorders. For that purpose, the WP with finger probe and chest sensor will be worn by the subject simultaneous to PSG in a sleep study at the clinical sleep lab. A PSG system will be recording the PSG data.",[31],[468,469,470,471,472],"WatchPAT","Polysomnography","ambulatory device","sleep apnea","apnea-hypopnea index","2025-08-18",{"date":475,"type":41},"2025-08-22",{"date":477,"type":41},"2022-09-19",{"date":383,"type":23},{"name":480,"class":256},"Itamar-Medical, Israel",3,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":49},"100457882","the-role-of-circadian-factors-in-regulation-of-neuroplasticity-in-ischemic-stroke-observational-100457882","NCT05242393","The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Observational)","Inclusion Criteria:\n\n* acute (symptom onset to admission \\\u003C1 days) ischemic stroke\n* ischemic stroke affecting the branches of anterior cerebral artery, middle cerebral artery and posterior cerebral artery\n* age 18-80 years\n* moderate or severe stroke (National Institutes of Health Stroke Scale, NIHSS\\>=5)\n* intravascular stroke treatment with thrombolysis or thrombectomy leading to satisfactory reperfusion (if applicable)\n* informed consent\n\nExclusion Criteria:\n\n* secondary parenchymal hemorrhage (\\>hemorrhage index -2)\n* clinically unstable or life-threatening conditions\n* known progressive neurological diseases\n* known psychiatric diseases\n* concomitant benzodiazepine medication\n* drug or alcohol abuse\n* pregnancy\n* disability to participate in the study\n* congestive heart failure with reduced ejection fraction (\\\u003C=45%) or New York Heart Association (NYHA) classification III-IV functional class","80 Years",{"count":490,"type":23},250,"The study is aimed at the investigation of the association of biomarkers of circadian rhythms with sleep characteristics and stroke outcome in acute stroke patients. It is designed as an observational cohort study with the retrospective and prospective longitudinal arms.",[493,31],"Stroke, Ischemic",[495,496,497,498,499,500,501,502],"neuroplasticity","cognitive dysfunction","disability","circadian rhythm","functional deficit","stroke outcome","sleep-disordered breathing","heart rate variability","2025-08-05",{"date":505,"type":41},"2025-08-08",{"date":507,"type":41},"2018-05-01",{"date":509,"type":23},"2026-12-31",{"name":511,"class":48},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":122,"minAge":58,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":62,"phases":522,"briefSummary":523,"conditions":524,"keywords":541,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":49},"100597441","therapeutic-writing-for-adults-suffering-from-chronic-pain-and-comorbid-mental-health-disorders-100597441","NCT07058532","Therapeutic Writing for Adults Suffering From Chronic Pain and Comorbid Mental Health Disorders","Therapeutic Writing Intervention in Pain Rehabilitation","TWfCP&MH","Inclusion Criteria:\n\n* Adult women (18 years or older), assigned female at birth and self-identify as women\n* Diagnosed with or experience of chronic, widespread (non-cancer) pain lasting at least two years\n* Diagnosed with or living with one or more mild mental health disorders (e.g., anxiety, mild depression), without current or past severe psychiatric conditions\n* Diagnosed with or experience of nociplastic pain (e.g., fibromyalgia)\n* Not currently using medications that may impair cognitive functioning (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Able to attend approximately 11 in-person visits over a 3-month period\n* Willing and able to participate in a structured therapeutic writing intervention\n* Purposefully selected to reflect a range of lived experiences relevant to the study's aims\n\nExclusion Criteria:\n\n* Presence of severe mental health disorders (e.g., schizophrenia, bipolar disorder, severe depression, or other psychotic conditions)\n* Use of medications known to impair memory, attention, or decision-making (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Participation in other concurrent treatments that may influence study outcomes\n* Cognitive limitations that would hinder meaningful engagement in the writing intervention\n* Individuals not assigned female at birth or who do not identify as women",{"count":521,"type":23},5,[97],"The goal of this observational study is to understand the effects and experiences of therapeutic writing interventions in adult women with chronic pain and co-occurring mental health conditions. The main questions it aims to answer are:\n\nCan therapeutic writing help relieve chronic pain and emotional distress?\n\nHow does writing support emotional processing, regulation, and meaning-making during rehabilitation?\n\nParticipants will take part in a two-part writing intervention involving:\n\nGuided writing exercises that focus on emotional processing, emotion regulation, and creating meaning.\n\nIndividual interviews after the writing sessions to explore their experiences.\n\nThe study uses qualitative analysis methods-phenomenology and logotherapy-to better understand how these writing interventions may support recovery, improve well-being, and offer non-pharmacological tools for managing chronic pain and mental health challenges.",[525,526,527,528,529,530,531,532,533,534,535,536,537,538,31,539,540],"Chronic Pain","Mental Health Disorder","Psychiatric &Amp;Amp;or Mood Disorder","Psychiatric Comorbidities","Psychiatric Diagnosis","Emotional Pain","Emotional Distress","Emotion Regulation","Emotional Processing","Meaning of Life","Meaning Made","Meaning of Life and Life Satisfaction","Depressive Disorder","Anxiety Disorders","Comorbid Depression","Process, Acceptance",[542,543,544,545,546,547,548,549,550,551,552,553,554,555],"Therapeutic writing","Chronic pain","Mental health disorders","Psychiatric disorders","Emotion regulation","Emotional processing","Meaning-making","Non-pharmacological intervention","Logotherapy","Phenomenological analysis","Psychosocial rehabilitation","Pain management","Pain coping","Creative writing","2025-06-30",{"date":558,"type":41},"2025-07-10",{"date":560,"type":23},"2025-08",{"date":562,"type":23},"2026-04",{"name":564,"class":48},"Toni Salikka",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":294,"maxAge":573,"enrollmentInfo":574,"targetDuration":4,"studyType":62,"phases":575,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":49},"100489161","sleep-impairment-in-subjects-at-risk-of-developing-alzheimers-disease-100489161","NCT05649514","Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease","Objective Sleep Impairment in APOEε4\u002Fε4 Subjects at Risk of Developing Alzheimer's Disease: Risk Factor for Cognitive Decline?","WAVE-APOE4","Inclusion Criteria:\n\n* Diagnosis of mild Alzheimer's disease with a MMS between 21-30\n* Without anticholinesterase and\u002For memantine treatment or on stable doses for at least 3 months\n* No antidepressant or anxiolytic treatment or stopped for at least 15 days\n* The presence of a family carer to complete neuropsychological scales, questionnaires and sleep diaries\n* Signed informed consent\n* Able to carry out all visits and follow study procedures\n* Affiliation to the French social security system\n\nExclusion Criteria:\n\n* Genetic form of alzheimer's disease\n* Insufficient clinical and paraclinical information for the diagnosis of AD\n* Patient living in a nursing home\n* Illiteracy or inability to perform psycho-behavioural tests\n* Major physical or neurosensory problems that may interfere with the tests\n* Patient deprived of liberty, by judicial or administrative decision;\n* Major depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)\n* Major protected by law;\n* Short-term life-threatening conditions","85 Years",{"count":22,"type":23},[97],"Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.\n\nTreatment protocols in the field of Alzheimer's disease (AD) are directed towards participants at risk of developing the disease, such as those who carry at least one ε4 allele on apolipoprotein E (APOE ε4). An individual with 2 ε4 copies has a 30-55% risk of developing AD with an age of onset around 68 years and a dose effect of the allele on risk and age of onset of symptoms.",[578,579,31],"Neuropathology","Cognitive Decline",[581,582,583,584],"cognitive composite score","sleep","biomarkers","cognitive decline","2025-06-23",{"date":587,"type":41},"2025-06-27",{"date":589,"type":41},"2025-02-05",{"date":591,"type":23},"2027-12-01",{"name":593,"class":48},"University Hospital, Montpellier",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":396,"enrollmentInfo":601,"targetDuration":4,"studyType":62,"phases":602,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":49},"100593767","phase-1-improving-sleep-in-a-psychiatric-hospital-100593767","NCT07010718","Improving Sleep in a Psychiatric Hospital","Comparative Effectiveness Trial of Sleep Promotion vs. Disruption in High Suicide Risk Inpatients","Inclusion Criteria:\n\n* Admitted voluntarily to inpatient psychiatric hospital for suicidal ideation or behavior.\n* Continue to express suicide risk on the Suicide Behaviors Questionnaire-Revised (SBQ-R) of ≥8 at admission.\n* Cognitive ability as tested by the Montreal Cognitive Assessment (MoCA) of \\> 23.\n* Have sufficient communication and comprehension ability to consent to the study\n* English speaking\n\nExclusion Criteria:\n\n* Intellectual disability\u002Funable to give informed consent.\n* Patients with one-to-one supervision or 15-minute (Q15) safety checks for suicidality or aggression will be unable to enroll in the study until these restrictions are discontinued.\n* Patients with roommates that are on one-to-one supervision or Q15 safety checks for suicidality or aggression.\n* Patients enrolled in the study with a patient admitted as their roommate who requires one-to-one supervision or Q15 checks-Patient will be unenrolled if a room change is not possible.",{"count":5,"type":23},[64],"The purpose of this study is to examine effects of sleep promotion versus treatment as usual (TAU) on subjective, self-reported sleep while in inpatient psychiatric treatment, to examine effects of sleep promotion vs. TAU\u002Fsleep disruption on self-reported depression, anxiety, suicide risk across inpatient length of stay, readmission at 72 hours, objective sleep and to compare implementation outcomes of acceptability and feasibility of sleep promotion relative to TAU\u002Fsleep disruption as reported by patients, clinicians, and clinic leaders using mixed methods.",[31,605],"Mental Health Issue",[607],"suicidal ideation","2025-05-30",{"date":610,"type":41},"2025-06-08",{"date":612,"type":23},"2025-06-01",{"date":614,"type":23},"2028-06-01",{"name":616,"class":48},"The University of Texas Health Science Center, Houston",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":626,"conditions":627,"keywords":631,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":49},"100548920","machine-learning-based-longitudinal-study-of-post-icu-syndrome-development-trajectory-in-critically-ill-patients-and-construction-of-clinical-early-warning-models-a-research-protocol-for-longitudinal-study-100548920","NCT06427265","Machine Learning-based Longitudinal Study of Post-ICU Syndrome Development Trajectory in Critically Ill Patients and Construction of Clinical Early Warning Models: a Research Protocol for Longitudinal Study","Inclusion Criteria patients :\n\n* Length of stay in ICU ≥24h;\n* Age ≥18 years old;\n* Conscious when leaving ICU, communicating with investigators without barriers;\n* Informed consent. Family members：\n* One family member ≥18 years of age was selected for each patient;\n* Assume the main role of caring for patients and medical decision-making;\n* No history of mental illness or other serious organic diseases;\n* Informed consent and voluntary participation in this study.\n\nExclusion Criteria patients :\n\n* Have been in ICU for more than 24h within 3 months before this admission;\n* Transferred to another ICU;\n* Cognitive impairment existed before ICU admission (BDRS \\> 4 points);\n* Severe hearing impairment, dysarthria, etc., which cannot be followed up;\n* Unable to complete the questionnaire survey due to serious illness.\n\nFamily members:\n\n* Family members refuse to participate in the study due to their own reasons;\n* Severe hearing and language impairment, unable to cooperate with researchers.","100 Years",{"count":625,"type":23},840,"This project intends to track and evaluate whether post-ICU syndrome will occur 7 days, 1 month, 3 months and 6 months after ICU patients are transferred out of the ICU through a longitudinal study, apply the latent category growth model to identify different trajectory patterns of post-ICU syndrome in critically ill patients, and use modern machine learning models to build an early warning model of the trajectory patterns of post-ICU syndrome.",[628,629,446,31,630],"Intensive Care Unit Syndrome","Prediction","Memory Disorders",[632,633,634],"Post-icu syndrome","Prediction model","Development Trajectory","2025-05-26",{"date":637,"type":41},"2025-05-31",{"date":639,"type":41},"2023-12-01",{"date":38,"type":23},{"name":642,"class":48},"The Affiliated Hospital Of Guizhou Medical University",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":573,"enrollmentInfo":651,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":653,"conditions":654,"keywords":664,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":286},"100590434","multimodal-imaging-and-biospecimen-collection-for-low-back-pain-lbpb-100590434","NCT06967363","Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)","Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Brain Function in Low Back Pain Patients: a Longitudinal Cohort Study","LBPB","Inclusion Criteria:\n\n1. Adults aged 18 to 80 years.\n2. Diagnosis of low back pain, defined as pain located between the lower costal margins and the gluteal folds, with or without leg pain.\n3. Eligible for surgical or non-surgical treatments.\n4. Willingness to undergo neuroimaging (fMRI), microbiota sampling, psychological assessments, and other related study procedures. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe neurological deficits requiring emergency surgery.\n2. Antibiotic or probiotic use within the past 4 weeks. Suffering from digestive diseases such as irritable bowel syndrome, gastric ulcer, duodenal ulcer, etc.;\n3. Diagnosed spinal infections, tumors, fractures, or inflammatory diseases (e.g., ankylosing spondylitis).\n4. Known severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) that would interfere with study participation.Head trauma; history of substance abuse.\n5. Contraindications to MRI scanning (e.g., pacemaker, metallic implants, severe claustrophobia).\n6. Pregnant or breastfeeding women.\n7. Participation in another interventional clinical trial within the past 3 months.\n8. Working at night shifts or travelling across time zones in the past 6 months.\n9. Excessive consumption of coffee, tea.",{"count":652,"type":23},360,"This prospective cohort study investigates the neurobiological, genetic, and psychosocial mechanisms underlying acute and chronic low back pain (LBP). Core objectives include establishing a high-quality biobank to support future research in connectomics, genomics, and biomarker discovery, and identifying predictors of pain progression and treatment response.\n\nThe study will also assess the impact of comorbid conditions such as anxiety, depression, and sleep disturbances on pain perception and clinical outcomes. Longitudinal analyses will explore the dynamic interplay between emotion, cognition, sleep, and pain to inform precision, mechanism-based interventions.\n\nFunctional imaging will be used to examine brain responses to nociceptive modulation, aiming to identify neural circuits involved in pain chronification. By integrating multimodal data-including neuroimaging, neurophysiology, microbiota profiling, polysomnography, and molecular assays-the study will define LBP subtypes, with a particular focus on nociceptive, neuropathic, and nociplastic mechanisms. The ultimate goal is to establish prognostic biomarkers and advance personalized strategies for LBP prevention and treatment.",[655,656,657,525,658,659,31,660,661,662,663],"Chronic Low Back Pain (CLBP)","Acute Low Back Pain","Low Back Pain","Acute Pain","Mental Disorders","Fibromyalgia (FM)","Nociplastic Pain","Neuropathic Pain","Nonspecific Low Back Pain",[665,666,667,668,669,670],"chronic low pack pain","fMRI","brain function","microbiota","nociplastic pain","treatment","2025-05-02",{"date":673,"type":41},"2025-05-13",{"date":675,"type":23},"2025-05-15",{"date":677,"type":23},"2028-12-31",{"name":679,"class":48},"Peking University Third Hospital",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":690,"conditions":691,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":693,"startDateStruct":695,"completionDateStruct":697,"leadSponsor":699,"locationsCount":49},"100541805","sleeping-quality-and-chronic-ocular-diseases-100541805","NCT06334640","Sleeping Quality and Chronic Ocular Diseases","L'Impatto Del Sonno Nelle Patologie Croniche Oculari","SONNO-OCU","Inclusion Criteria:\n\n* Patients with macular degeneration or glaucoma or\n* Healthy volunteers\n\nExclusion Criteria:\n\n\\- Patients with other ocular disorders",{"count":689,"type":23},186,"To assess the impact of sleep quality on chronic eyes diseases",[31],"2025-04-30",{"date":694,"type":41},"2025-05-04",{"date":696,"type":41},"2023-10-17",{"date":698,"type":23},"2025-12-31",{"name":455,"class":48},{"id":701,"slug":702,"hasResults":12,"nctId":703,"briefTitle":704,"officialTitle":705,"acronym":4,"eligibilityCriteria":706,"healthyVolunteers":12,"sex":18,"minAge":707,"maxAge":488,"enrollmentInfo":708,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":710,"conditions":711,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":715,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":720,"locationsCount":49},"100586368","neural-mechanisms-and-clinical-applications-of-dbs-for-modulating-sleep-dysregulation-in-pd-100586368","NCT06914466","Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD","Neural Mechanisms and Clinical Applications of Deep Brain Stimulation for Modulating Sleep Dysregulation in Parkinson's Disease","Inclusion Criteria:\n\n1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's disease were made by three neurologists who were experienced in the field of movement disorders.\n2. Patients who underwent bilateral STN-DBS(Medtronic Percept™ PC)\n3. Patients who can cooperate with the completion of postoperative follow-up and clinical evaluation.\n\nExclusion Criteria:\n\n1. Patients who underwent other brain surgery;\n2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;\n3. Patients with other central nervous system and peripheral nervous system diseases;\n4. Patients complicated with severe medical system diseases, or unable to tolerate clinical evaluation;\n5. Patients with severe mental illness;\n6. Patients who cannot complete informed consent due to cognitive and communication barriers, or refuse to sign informed consent.","19 Years",{"count":709,"type":23},20,"Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however, non-motor symptoms such as sleep disorders significantly impair patients' quality of life. While preliminary evidence suggests DBS may improve sleep, the underlying neural mechanisms and long-term effects on sleep regulation remain poorly elucidated. This study employs a wearable polysomnography (PSG) device to investigate how STN-DBS modulates sleep architecture, local field potentials (LFPs), and clinical outcomes in PD patients. We hypothesize that STN-DBS contributes to both the regulation and disruption of normal sleep behavior. By synchronizing PSG with STN-LFP recordings under DBS-ON and DBS-OFF conditions, we aim to decode sleep stages using STN-LFPs, characterize PD-specific sleep abnormalities (e.g., sleep architecture, atonia), and analyze DBS-induced LFP changes and their correlations with clinical efficacy. According to the above data, the sleep stage characteristics were decoded, and the algorithm was used to determine the optimal clinical threshold current amplitude to improve sleep. Then, the patients will be given adaptive stimulation, and the sleep quality was monitored to verify its efficacy.This study will provide a neurophysiological foundation for developing closed-loop stimulation strategies targeting sleep dysfunction in PD.",[712,713,31],"Deep Brain Stimulation","Parkinson's Disease and Parkinsonism","2025-03-30",{"date":716,"type":41},"2025-04-06",{"date":718,"type":41},"2024-09-01",{"date":253,"type":23},{"name":721,"class":48},"Xuanwu Hospital, Beijing"]